Abstract
TO THEEDITOR: The editorial 1 regarding the publication by Soulos et al 2 stated that some older women with breast cancer are being clearly overtreated. Most clinicians will agree with this statement. However, the author also indicated that “offering radiation therapy to a woman with a good-prognosis tumor and a life expectancy of less than 5 years does not seem indicated.” 1(p1578) Although this statement represents a publicly shared standard, 3,4 it is not supported by facts. Several studies have evaluated the role of adjuvant radiotherapy, and all indicated a benefit of radiotherapy in reducing locoregional recurrence rates. 5-11 The Toronto Breast Cancer Study indicated that the relapse rate was 1.2% with tamoxifen alone and decreased to 0% when tamoxifen was given with whole-breast irradiation (WBI). There were no significant differences in the distant recurrence rates, questioning the role of tamoxifen alone in controlling systemic disease in this subgroup of patients. 7 The Cancer and Leukemia Group B 9343 trial published in the same issue of New England Journal of Medicine concurred with the results of the Toronto group. In this study, women age 70 years with tumors 2 cm were assigned to tamoxifen either with or without WBI. The locoregional control recurrence rates were lower in the combined WBI-tamoxifen group (1% v 4%; P .001). 6 These results were supported in a later update abstract presented in 2010, where the only significantly different outcome was local recurrence with a difference of 2% in the irradiated group and 9% in those women who did not receive adjuvant radiotherapy. 5 In view of these facts, it is not clear why omitting radiotherapy in older patients with low-risk disease has become a publicly shared standard. Maybe it is because there were no significant differences between the two groups with regard to the rates of mastectomy for local recurrence, distant metastases, or 5-year rates of overall survival. 3,5-7,12 Giordano 1 commented that older women with low-risk breast cancer treated with adjuvant radiotherapy are at risk for unnecessary adverse effects, inconvenience of treatment, and possibly increased personal costs for a treatment unlikely to offer them any benefit. This could also be applied to the endocrine treatment, as both classes of endocrine agents have their own recognized adverse effects and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have